Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Published online Nov 15, 2026. doi: 10.4251/wjgo.123385
Table 1 Baseline characteristics of hepatocellular carcinoma patients treated with second-line regorafenib combination with programmed cell death-1 inhibitor or monotherapy, n (%)
| Characteristics | Overall (n = 140) | R group (n = 39) | RP group (n = 101) | P value |
| Age | 0.811 | |||
| < 65 | 99 (70.7) | 27 (69.2) | 72 (71.3) | |
| ≥ 65 | 41 (29.3) | 12 (30.8) | 29 (28.7) | |
| Gender | 0.652 | |||
| Female | 22 (15.7) | 7 (17.9) | 15 (14.9) | |
| Male | 118 (84.3) | 32 (82.1) | 86 (85.1) | |
| Smoking | 0.839 | |||
| No | 95 (67.9) | 28 (71.8) | 67 (66.3) | |
| Yes | 39 (27.9) | 10 (25.6) | 29 (28.7) | |
| Unknown | 6 (4.3) | 1 (2.6) | 5 (5.0) | |
| Drinking | 0.203 | |||
| No | 103 (73.6) | 26 (66.7) | 77 (76.2) | |
| Yes | 30 (21.4) | 12 (30.8) | 18 (17.8) | |
| Unknown | 7 (5.0) | 1 (2.6) | 6 (5.9) | |
| Hepatitis B infection | 0.908 | |||
| No | 31 (22.1) | 8 (20.5) | 23 (22.8) | |
| Yes | 107 (76.4) | 31 (79.5) | 76 (75.2) | |
| Unknown | 2 (1.4) | 0 (0.0) | 2 (2.0) | |
| Hepatitis C infection | 0.106 | |||
| No | 134 (95.7) | 38 (97.4) | 96 (95.0) | |
| Yes | 1 (0.7) | 1 (2.6) | 0 (0.0) | |
| Unknown | 5 (3.6) | 0 (0.0) | 5 (5.0) | |
| Diabetes | 1.000 | |||
| No | 126 (90.0) | 36 (92.3) | 90 (89.1) | |
| Yes | 13 (9.3) | 3 (7.7) | 10 (9.9) | |
| Unknown | 1 (0.7) | 0 (0.0) | 1 (1.0) | |
| Hypertension | 0.285 | |||
| No | 99 (70.7) | 25 (64.1) | 74 (73.3) | |
| Yes | 41 (29.3) | 14 (35.9) | 27 (26.7) | |
| First-line ICI therapy | 0.224 | |||
| No | 53 (37.9) | 14 (35.9) | 39 (38.6) | |
| Yes | 72 (51.4) | 18 (46.2) | 54 (53.5) | |
| Unknown | 15 (10.7) | 7 (17.9) | 8 (7.9) | |
| Tumor size | 0.323 | |||
| ≤ 5 cm | 46 (32.9) | 12 (30.8) | 34 (33.7) | |
| > 5 cm | 25 (17.9) | 10 (25.6) | 15 (14.9) | |
| Unknown | 69 (49.3) | 17 (43.6) | 52 (51.5) | |
| CNLC | 0.715 | |||
| IIa + IIb | 50 (35.7) | 13 (33.3) | 37 (36.6) | |
| IIIa + IIIb | 90 (64.3) | 26 (66.7) | 64 (63.4) | |
| Child-Pugh class | 0.714 | |||
| A | 74 (52.9) | 22 (56.4) | 52 (51.5) | |
| B | 21 (15.0) | 5 (12.8) | 16 (15.8) | |
| C | 2 (1.4) | 0 (0.0) | 2 (2.0) | |
| Unknown | 43 (30.7) | 12 (30.8) | 31 (30.7) | |
| ECOG PS | ||||
| 0 | 22 (15.7) | 5 (12.8) | 17 (16.8) | 0.908 |
| 1 | 26 (18.6) | 9 (23.1) | 17 (16.8) | |
| 2 | 9 (6.4) | 2 (5.1) | 7 (6.9) | |
| 3 | 1 (0.7) | 0 (0.0) | 1 (1.0) | |
| Unknown | 82 (58.6) | 23 (59.0) | 59 (58.4) | |
| Portal vein invasion tumor | ||||
| No | 66 (47.1) | 19 (48.7) | 47 (46.5) | 0.702 |
| Yes | 30 (21.4) | 9 (23.1) | 21 (20.8) | |
| Unknown | 44 (31.4) | 11 (28.2) | 33 (32.7) | |
| Sites of metastasis | ||||
| Lung | 28 (45.2) | 9 (40.9) | 19 (47.5) | |
| Bone | 8 (12.9) | 3 (13.6) | 5 (12.5) | |
| Lymph node | 16 (25.8) | 6 (27.3) | 10 (25.0) | |
| Others | 10 (16.1) | 4 (18.2) | 6 (15.0) | |
| Laboratory indicators, median [IQR] | ||||
| Platelet (× 109/L) | 151.00 [111.00, 217.25] | 152.00 [110.50, 178.00] | 151.00 [111.00, 222.00] | 0.577 |
| Hemoglobin (g/L) | 132.00 [107.00, 144.25] | 127.00 [114.50, 145.50] | 134.00 [107.00, 143.00] | 0.961 |
| ALT (IU/L) | 35.00 [23.00, 65.00] | 37.00 [23.00, 54.00] | 34.00 [23.00, 73.00] | 0.705 |
| AST (IU/L) | 41.50 [29.00, 82.75] | 46.00 [31.00, 104.00] | 41.00 [27.00, 74.00] | 0.265 |
| ALB (g/L) | 39.70 [36.12, 43.90] | 39.70 [36.45, 43.90] | 39.70 [36.20, 43.90] | 0.917 |
| TBIL (μmol/L) | 17.20 [11.15, 23.30] | 16.30 [13.20, 26.30] | 17.30 [10.65, 21.90] | 0.430 |
| DBIL (μmol/L) | 7.95 [5.18, 11.73] | 7.70 [5.00, 12.00] | 8.00 [5.20, 11.35] | 0.631 |
| PT (s) | 12.55 [11.80, 13.55] | 12.70 [11.90, 13.85] | 12.50 [11.70, 13.30] | 0.503 |
| INR | 1.03 [0.98, 1.11] | 1.04 [0.90, 1.10] | 1.02 [0.99, 1.13] | 0.465 |
| AFP (ng/mL) | 124.20 [7.60, 2000.00] | 101.10 [7.85, 1978.90] | 124.20 [7.20, 2403.61] | 0.970 |
| Initial daily dose of regorafenib | ||||
| 40 mg | 6 (4.3) | 1 (2.6) | 5 (5.0) | 0.057 |
| 80 mg | 65 (46.4) | 13 (33.3) | 52 (51.5) | |
| 120 mg | 12 (8.6) | 6 (15.4) | 6 (5.9) | |
| 160 mg | 18 (12.9) | 5 (12.8) | 13 (12.9) | |
| Unknown | 39 (27.9) | 14 (35.9) | 25 (24.8) |
- Citation: Ma F, Zheng LY, Song DJ, Zhao ZW, Cao F, Hao WY, Qiu JQ, Lu D, Zheng JP. Regorafenib combined with programmed death inhibitor after initial treatment failure in unresectable hepatocellular carcinoma. World J Gastrointest Oncol 2026; 18(11): 123385
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/123385.htm
- DOI: https://dx.doi.org/10.4251/wjgo.123385